US OptionsDetailed Quotes
ANAB250117P5000
- 0.03
- 0.000.00%
15min DelayClose Dec 24 13:00 ET
0.00High0.00Low
0.03Open0.03Pre Close0 Volume20 Open Interest5.00Strike Price0.00Turnover199.87%IV64.22%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier23DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type-0.0107Delta0.0041Gamma463.00Leverage Ratio-0.0041Theta-0.0001Rho-4.95Eff Leverage0.0010Vega
AnaptysBio Stock Discussion
Sign in to post a comment
$AnaptysBio (ANAB.US)$ Reuters· 3 mins ago
AnaptysBio Inc - Anb032 Ad Trial and All Further Investment Will Be Discontinued
AnaptysBio Inc - Anb032 Ad Trial and All Further Investment Will Be Discontinued
1
2
$AnaptysBio (ANAB.US)$ looking good got smacked last timee it tested $40.. needs to break that on heavy volume 🤔
$AnaptysBio (ANAB.US)$
NEWS
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
Positive
Significant improvement in skin clearance for patients receiving imsidolimab in the Phase 3 trials
Excellent maintenance of skin clearance with no flares in patients on monthly maintenance dosing of imsidolimab
Positive safety and tolerability profile with no treatment-related serious adverse events reported
Low incidence ...
NEWS
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
Positive
Significant improvement in skin clearance for patients receiving imsidolimab in the Phase 3 trials
Excellent maintenance of skin clearance with no flares in patients on monthly maintenance dosing of imsidolimab
Positive safety and tolerability profile with no treatment-related serious adverse events reported
Low incidence ...
1
$AnaptysBio (ANAB.US)$
NEWS
Anaptys To Receive $50 Mln In Capped Non-Recourse Monetization From Amended Agreement With Sagard In Exchange For Additional Jemperli Royalties
NEWS
Anaptys To Receive $50 Mln In Capped Non-Recourse Monetization From Amended Agreement With Sagard In Exchange For Additional Jemperli Royalties
1
$Travere Therapeutic (TVTX.US)$ Phase 3
$CG Oncology (CGON.US)$ Phase 3
$United Therapeutics (UTHR.US)$ Phase 3
$United Therapeutics (UTHR.US)$ Phase 3
$BioCardia (BCDA.US)$ Phase 3
$Insmed (INSM.US)$ Phase 3
$GlycoMimetics (GLYC.US)$ Phase 3
$Annexon (ANNX.US)$ Phase 3
$Lipocine (LPCN.US)$ Phase 3
$FibroGen (FGEN.US)$ Phase 3
$UroGen Pharma Ltd (URGN.US)$ Phase 3
$Lyra Therapeutics (LYRA.US)$ Phase 3
$Citius Pharmaceuticals (CTXR.US)$ Phase 3
$Jaguar Health (JAGX.US)$ Phas...
$CG Oncology (CGON.US)$ Phase 3
$United Therapeutics (UTHR.US)$ Phase 3
$United Therapeutics (UTHR.US)$ Phase 3
$BioCardia (BCDA.US)$ Phase 3
$Insmed (INSM.US)$ Phase 3
$GlycoMimetics (GLYC.US)$ Phase 3
$Annexon (ANNX.US)$ Phase 3
$Lipocine (LPCN.US)$ Phase 3
$FibroGen (FGEN.US)$ Phase 3
$UroGen Pharma Ltd (URGN.US)$ Phase 3
$Lyra Therapeutics (LYRA.US)$ Phase 3
$Citius Pharmaceuticals (CTXR.US)$ Phase 3
$Jaguar Health (JAGX.US)$ Phas...
20
4
🎯 Ph 3 readouts in Q2 2024...
$Intra-Cellular Therapies (ITCI.US)$ Phase 3
$CG Oncology (CGON.US)$ Phase 3
$Hutchmed (China) (HCM.US)$ Phase 3
$Viracta Therapeutics (VIRX.US)$ Phase 3
$GlycoMimetics (GLYC.US)$ Phase 3
$Annexon (ANNX.US)$ Phase 3
$Lipocine (LPCN.US)$ Phase 3
$FibroGen (FGEN.US)$ Phase 3
$UroGen Pharma Ltd (URGN.US)$ Phase 3
$Lyra Therapeutics (LYRA.US)$ Phase 3
$Citius Pharmaceuticals (CTXR.US)$ Phase 3
$Marinus Pharmaceuticals (MRNS.US)$ Phase 3
$BioCardia (BCDA.US)$ Phase 3 ...
$Intra-Cellular Therapies (ITCI.US)$ Phase 3
$CG Oncology (CGON.US)$ Phase 3
$Hutchmed (China) (HCM.US)$ Phase 3
$Viracta Therapeutics (VIRX.US)$ Phase 3
$GlycoMimetics (GLYC.US)$ Phase 3
$Annexon (ANNX.US)$ Phase 3
$Lipocine (LPCN.US)$ Phase 3
$FibroGen (FGEN.US)$ Phase 3
$UroGen Pharma Ltd (URGN.US)$ Phase 3
$Lyra Therapeutics (LYRA.US)$ Phase 3
$Citius Pharmaceuticals (CTXR.US)$ Phase 3
$Marinus Pharmaceuticals (MRNS.US)$ Phase 3
$BioCardia (BCDA.US)$ Phase 3 ...
16
4
Despite a recent rebound, AnaptysBio's share price is far from regaining investors' confidence after substantial losses over the past five years. Market fears over consistent lack of profitability persist, despite revenue growth.
$AnaptysBio (ANAB.US)$ Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) HALT off at 8:30 AM est![]()
No comment yet
HannChau : short it i guess
HannChau HannChau : cant short because it is suspended.